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ABSTRACT 27
Loss-of-function (LoF) screenings have the potential to reveal novel cancer-specific 28
vulnerabilities, prioritize drug treatments, and inform precision medicine therapeutics. 29
These screenings were traditionally done using shRNAs, but with the recent emergence 30 of CRISPR technology there has been a shift in methodology. However, recent analyses 31
have found large inconsistencies between CRISPR and shRNA essentiality results. Here, 32
we examined the DepMap project, the largest cancer LoF effort undertaken to date, and 33 find a lack of correlation between CRISPR and shRNA LoF results; we further 34 characterized differences between genes found to be essential by either platform. We 35 then introduce ECLIPSE, a machine learning approach, which combines genomic, cell 36 line, and experimental design features to predict essential genes and platform specific 37 essential genes in specific cancer cell lines. We applied ECLIPSE to known drug targets 38
and found that our approach strongly differentiated drugs approved for cancer versus 39 those that have not, and can thus be leveraged to identify potential cancer repurposing 40
opportunities. Overall, ECLIPSE allows for a more comprehensive analysis of gene 41 essentiality and drug development; which neither platform can achieve alone. between platforms and allows for a more complete understanding of gene essentiality. 97 98 RESULTS 99 100
Significant discrepancies between shRNA and CRISPR screens 101 102
To evaluate how shRNA and CRISPR screens could be used together to find essential 103 genes, we first turned to DepMap the largest, publically available shRNA and CRISPR 104
LoF screening efforts across diverse cancer cell lines 15, 17 . For each gene-cell line pair, 105
DepMap calculated an essentiality score -measuring the effect a given 106 knockdown/knockout had on the survival of that specific cell line -with lower scores 107 corresponding to more essential genes 18 . These scores were calculated using the 108 DEMETER and CERES algorithm for shRNA and CRIPSR screens, respectively. The 109 DEMETER algorithm specifically accounts for seed-mediate off-target effects 19 , while 110
CERES corrects for the noted copy number bias within CRISPR screens. We found that 111 when matching these gene-cell line pairs the correlation between shRNA and CRISPR 112 scores lacked strong concordance (corr = 0.2, p <0.001,Spearman Correlation, Fig S1A,  113 Supplementary Data). This low correlation could have drastic impacts as it indicates 114
that certain essential genes could be either missed or incorrectly called based on the 115 platform being used. 116 117
To decrease the inherent noise caused by genes that are not strongly essential 118
(intermediate DEMETER and CERES scores), we next separated each gene-cell line pair 119
into one of 4 categories based on the screening results from each platform: 1) called as 120 essential only by shRNA, 2) only by CRISPR, 3) by both platforms, or 4) by neither ( Fig.  121  1A) . For each platform, the top depleted genes within each cell line were defined as 122 essential (Methods). We observed that even for marked essential genes in shRNA there 123 was a broad distribution of essentiality scores within CRISPR, and vice versa with a 124 significant difference between the mean LoF scores (Mann-Whitney, p < 0.001, Fig. 1B-125 C). Platform specific essential (PSE) genes, genes called as essential exclusively by 126 shRNA or CRISPR, were the majority of all essential genes. Therefore, even for supposed 127 essential genes there is still a large degree of discordance between the platforms. 128 129
We next evaluated both platforms in their ability to identify predetermined known essential 130
genes. We first evaluated the performance of both shRNA and CRISPR in the 131 categorization of the essential gene list found in Hart et al 20 , and found that both platforms 132 performed extremely well (AUC = 0.97 for both, Fig. S1B ). However, this set of essential 133
genes was found using shRNA screens, therefore, to ensure a truly unbiased approach 134
in the evaluation of each platform we identified a set of essential genes based on the 135 frequency of loss of function and missense mutations across 60,706 individuals 21 . 136
Additionally, we included the genes classified as "essential by both" to measure the 137 performance of PSE and combined platform essentiality. To measure whether the 138 discordance we observed was simply because one platform was drastically outperforming 139 the other, we used this list as a "gold-standard" set of essential genes to objectively 140 measure the accuracy of each platform (Methods). We found that the essential genes 141 marked by both platforms were more likely to be part of our gold-standard set (Fisher's  142 exact test, OR = 20.4, p <0.001) than genes marked as essential by any single platform 143 (Fisher's Exact Test, OR = 6.3, OR = 8.3, p <0.001, for shRNA and CRISPR, respectively) 144 ( Fig. 1D, S2) . These findings indicate that the best identification of essential genes can 145 be obtained only by combining the output of CRISPR and shRNA LoF screens. 146 147
In addition to the identification of essential genes, cancer LoF screenings can serve as a 148 tool to identify effective drugs within certain cell lines. This is based on the hypothesis 149 that if a gene is essential within a specific cell line, a specific inhibitor of that gene should 150 efficiently kill cells grown from that cell line. To determine which type of essentiality best 151
identified anti-cancer drugs, we obtained drug efficacy values for a set of 170 cell lines 152
for 59 drugs, which had both shRNA and CRISPR screening data available for their 153 targets ( Fig. 1E, Methods) . We found that there was a significant increase in a cell line's 154 sensitivity to a drug if at least one of that drug's targets were marked as essential by both 155 CRISPR and shRNA compared to drugs that had no targets marked as essential by both 156 platforms (Mann-Whitney, Location Shift = -3.45, p <0.001). Interestingly, we observed 157 platform specific differences in identifying effective drugs. For instance, we found that 158 targets that were exclusively essential within shRNA screens had a larger increase in 159 efficacy than targets that were exclusively essential within CRISPR (Mann-Whitney, 160
Location shift = -2.91, p < 0.001 vs Location Shift = -1.73, p <0.001 for shRNA and 161 CRISPR, respectively, Fig, 1E ). This result indicates how shRNA screens may be more 162 applicable for drug prioritization than their CRISPR counterparts. One possible 163 explanation for this could be that the mechanism for shRNA knockdown is more similar 164
to how some compound antagonism modes of action work than the DNA-targeted gene 165 knockout induced by CRISPR 22 . However, the utilization of both CRISPR and shRNA, 166 similar to with the identification of essential genes, is best when identifying effective drugs. 167 168 169
Genomic features can help identify genes that will perform similarly across 170 platforms 171 172
Diving deeper into the discordance observed between shRNA and CRISPR screens, we 173 next sought to identify whether there were certain types of genes that produce similar 174 results across the two platforms vs. those that give highly discordant scores. If we can 175 identify which genes will give similar or opposing results across platforms, it could help 176 determine the utility of performing both screening experiments rather than only a single 177 one to test a single gene. For each gene, we measured the correlation between its 178 essentiality scores for shRNA and CRISPR across all overlapping cell lines. We then 179 separated genes into 3 categories based on this correlation: no correlation, negatively 180 correlated (opposing results), positively correlated (similar results) ( Fig. 2A. ) 181 182
We found that many genomic features were able to accurately separate genes based on 183 their cross-platform correlation (Methods). Genes that were highly correlated across the 184 two platforms tended to be more highly expressed in that specific cell lines and were more 185 highly conserved across species ( Fig. 2B-C) . In addition, we found that genes with similar 186 results across platforms tended be more connected in a curated protein-protein 187 interaction network (Methods, Fig. 2E-F) . This pattern of highly connected genes 188
performing similarly across platforms held true when examining the degree of regulation 189 between genes and multiple transcription factors ( Fig. 2D) . Previous studies have shown 190 that genes that are conserved, highly connected, and regulated by many transcription 191 factors are often essential to survival 23, 24 . Therefore, we next compared cross-platform 192 correlation for each gene to its measured intolerance to loss of function mutations 21 -the 193 same feature we, and previous studies, have used to generate a gold standard list of 194 essential genes. As expected, genes that were more intolerant to loss of function 195 mutations (higher probabilities) were more likely to be positively correlated across 196 platforms ( Fig. 2G) . This finding was promising as it indicates that, the comparison of 197 results from both platforms will be consistent for this set of essential genes. However, we 198 did observe that even at high LoF intolerance probabilities there were a significant number 199 of genes that performed variably across the two platforms.
201
Features related to Platform Specific Essentiality (PSE) 202 203
To further examine genes with discordant results, we focused on how numerous genomic 204
and experimental design features differed across PSE genes, genes marked essential by 205
both platforms and those that would be found essential using either platform. Focusing 206
first on expression, we found that for the majority of the tested cell lines, genes identified 207 as essential by both platforms were significantly more highly expressed than genes 208 identified as essential by only one platform. Interestingly, PSE genes, genes exclusively 209 marked essential by shRNA or CRISPR, also showed a difference in expression, with 210 genes marked essential by CRISPR only have higher expression values ( Fig. 3A) .
211
Previously essential genes have been found to have higher expression 23, 25 ; therefore, 212 the combined findings from both platforms appears to produce the highest confidence 213 essential genes and CRISPR PSE genes also appear to follow more closely to classical 214 essential gene characteristics. Examining other genomic features (Methods), we found 215 a similar pattern where genes called as essential by both screens were more highly 216 conserved and interconnected in biological networks than shRNA specific essential genes 217
and CRISPR specific essential genes ( Fig. S3) . CRISPR PSE genes also demonstrated 218 these characteristics as well, albeit at a much smaller effect size. These gene 219 characteristics, high expression, high conservation and connected 23 , have been long 220 known to be associated with evolutionarily essential genes. We tested if CRISPR was 221 identifying cell line agnostic essential genes. To measure this, for each gene we 222 calculated what percentage of the 379 cell lines each platform marked said gene as 223 essential. We found that shRNA identifies significantly more cell line specific essential 224 genes compared to CRISPR ( Fig. 3B) . Therefore, these differences in genomic features 225 could point to the inherent variability between cancer specific essential genes being found 226 within shRNA and not CRISPR.
228
Furthermore, certain differences in other genomic characteristics could point towards 229 biases in either CRISPR or shRNA screens and these are important to consider when 230 designing future screens. From our findings and previous work 12 , each platform identifies 231 essential gene's associated with unique pathways (Fig. 3C) , such as shRNA essential 232 genes being enriched for RNA polymerase, across all cell lines more consistently than 233 CRISPR essential genes. While CRISPR essential genes are were consistently enriched 234
for DNA replication more often than shRNA essential genes (Methods). Other platform 235 specific biases, such as the design of the single-guide RNAs (sgRNA), a key component 236 of the CRISPR-Cas9 system shown to influence knock-out efficiency 26-28 , proved to 237 contribute to the discordance between shRNA and CRISPR. The likelihood of causing an 238 out of frame mutation was significantly lower in shRNA specific essential genes compared 239
to CRISPR specific essential genes ( Fig. 3D, S4) , which indicates erroneous results by 240
CRISPR. Perhaps designing more specific sgRNAs for shRNA specific genes would have 241 resulted in essential calls in CRISPR screens as well.
243 ECLIPSE predicts Platform-Specific Essentiality 244 245
Based on these results we reasoned that combining shRNA and CRISPR screens could 246
combat some of the pitfalls of each individual platform and provide more accurate 247 essentiality screening results. However, due to costs -both in terms of time and money 248 -it is often not feasible to use two separate technologies. To address this, we developed 249 ECLIPSE -the Estimation of Combined LoF scores and Inference of Platform Specific 250
Essentiality. ECLIPSE leverages the genomic features we found consistent with essential 251 genes, such as gene expression, network properties and conservation, in combination 252
with cell-line and design features to predict cell line specific essentiality results for both 253 platforms, as well as results specific to either platform, without any prior LoF results ( Fig.  254  4A) . 255 256
For each essentiality type (i.e.: marked essential by both, CRISPR specific essential, and 257
shRNA specific essential) a binary random forest classification model was built and 10-258
fold cross validation was used to evaluate performance ( Fig. 4A ). A separate model was 259
built for each essentiality type classification due to the highly variable imbalance between 260
classes (Table S1 ). For the same reason of class imbalance, we evaluated the 261 performance of these models in terms of the class-specific Area Under the Precision-262
Recall Curve (AUPRC) measure 29 in addition to the standard Area Under the Receiver 263
Operating Characteristic (ROC) Curve (AUC) score 30 . 264 265
The identification of the highest confidence essential genes, those called as essential by 266 both platforms, had significant predictive performance, achieving an AUC of 0.984 (S5).
267
Due to the large class imbalance in all of these models the AUPRC expected by random 268
is extremely low (AUPRC = 0.049), comparatively our model does significantly better and 269
achieves an AUPRC of 0.746 ( Fig. 4B) .
271
To enable the prediction of PSE, features known to contribute to platform biases were 272
included, such as sgRNA design and GC content of target strands. We found that 273 ECLIPSE performed comparably on identifying platform specific essential genes, with 274 significant predictive performance for shRNA specific essential and CRISPR specific 275 essential genes (AUC= 0.981, AUC= 0.938, respectively, Fig. S5 ). Again, we analyzed 276
the AUPRC and found that both PSE models performed better than random, with the 277 CRISPR-specific and shRNA-specific essentiality models achieving AUPRC of 0.678 and 278 0.546 respectively, as compared to those of their random counterparts (0.049 and 0.044 279 respectively) ( Fig. 4B) . 280 281
To understand the features that contribute to each of ECLIPSE's three classifications, we 282 measured the mean decrease in accuracy upon removal of each feature (Methods, Fig.  283 4C). We found that features such as conservation, expression and network degree were 284 important in each classification task. This analysis also revealed a subset of features that 285
were differentially valuable based on the type of essentiality being predicted. For instance, 286
we found that many of the sgRNA design features were more valuable in predicting 287
shRNA specific essential genes than compared to any other classification. In addition, the 288 number of isoforms of a gene was more informative in the classification of shRNA specific 289 essential genes, which we hypothesize arises from the mechanistic differences between 290
platforms. For example, shRNA is targeting mRNA, then if the seed sequence is not 291
robust enough to target all isoforms, this could lead to incomplete knockdowns 31 . 292 293
To test the performance of our model we used the results from a CRISPR LoF screening 294 conducted using kinase domain focused sgRNA library that has been previously 295 published 32, 33 . In total, there were 11 cell lines tested that were not used within the training 296 of ECLIPSE. We collected all available genomic, cell line and sgRNA design features as 297 described above. We ran all gene-cell line pairs through both the CRISPR specific 298 essential ECLIPSE model and essential by both ECLIPSE model. We found that the 299 genes classified as essential by either ECLIPSE model had significantly lower log fold 300 change compared to those predicted to be not essential (Mann-Whitney, Location Shift = 301 -2.83, p < 0.001, Figure 4C ). This CRISPR screen served as a valuable test set to prove 302
the utility of ECLIPSE to predict LoF screens done using a diverse set of cell lines, genes 303 and libraries. 304 305 306
ECLIPSE accurately predicts pharmacological response 307 308
We next investigated whether ECLIPSE's gene essentiality predictions in cell lines that 309 did not have prior shRNA and CRISPR screening data are predictive of pharmacological 310
response. We hypothesized that a drug will have better responses within cell lines where 311 its target(s) is predicted to be more essential. Therefore, we evaluated 60 drugs that had 312 publicly available pharmacological data across 212 cell lines. For each target-cell line pair 313
we used ECLIPSE to predict the gene's essentiality status, for all essentiality classes 314 (S6). For targets predicted to be essential by both platforms, we found that drugs targeting 315 these genes had significantly higher efficacy than drugs whose targets were predicted 316 non-essential (Mann-Whitney, Location Shift = 2.6, p < 0.001). Additionally, drugs with 317 gene targets predicted essential in shRNA only or CRISPR only were significantly more 318 efficacious than those drugs with targets predicted not essential (Mann-Whitney, Location 319 shift = 2.27 vs 2.31 for shRNA specific and CRISPR specific, respectively, p-value < 320 0.001).The ability to identify effective pharmacological response demonstrates that 321 ECLIPSE can be applied to cell lines to identify possible therapies based on the cancer 322 specific essentialities; which enables more precise drug selection and prioritization. 323
Overall this highlights how ECLIPSE can be used not only to understand mechanisms of 324 CRISPR and shRNA screens, but also to inform drug treatment in a cell-specific basis. 325 326
However, there are many situations where a drug can be highly efficacious in a cell line 327 yet perform poorly in the clinic. For example, if a drug is targeting a gene that is essential 328
within both cancerous and healthy cells, the drug might be highly toxic and likely not make 329 it past Phase 1 clinical trials, if that. Therefore, we must consider two things, first that a 330 gene will be essential within a cell line and second that a gene's essentiality is highly 331 specific (either to all cancer cells vs healthy cells or a specific cancer cell type). To do this 332
we modified our predicted ECLIPSE score to create a Target Score, which is an 333
integration of ECLIPSE scores across all cell lines (see Methods). The Target Score will 334 equally weigh both efficacy and specificity. We next tested if our Target Score could be 335
used to identify clinically relevant cancer therapeutics. We ran all known targets of 333 336 drugs approved to treat cancer and 6,013 drugs not currently approved or investigated to 337 treat cancer through ECLIPSE and calculated the Target Score for each drug (Methods).
338
We found that approved cancer drugs had significantly higher Target Scores compared 339
to drugs not approved for any cancer indication (Figure 5) . Overall, using the ECLIPSE 340 essential by both model proved to be the most effective in the identification of cancer 341 drugs (Mann-Whitney, Location Shift = 0.22, p-value < 0.001), however both CRISPR 342 specific and shRNA specific models also showed statistical significance in the 343 differentiation of cancer and non-cancer drugs. As expected, using only the raw ECLIPSE 344 score in place of the Target Score did not show as great of a difference in approved and 345 non-approved cancer drugs, however there was still a significant difference between the 346 drug categories for each platform (Fig. S7) Since the first application of RNAi, genome-wide loss-of-function (LoF) screens have 399 been instrumental in the identification of essential genes, however as genetic LoF can 400
have varying consequences and efficacies, the data from these screens needs to be 401 thoughtfully examined. Previous reports have highlighted how RNAi platforms, such as 402
shRNA, and the CRISPR-Cas9 system can have discordant results, however these 403 analyses were done on only a single cell type without presenting any global feature based 404
analysis. Here we compare shRNA and CRISPR screening results on a panel of 379 405 cancer cell lines spanning multiple different tumor types, which resulted in highly 406 discordant results with many platform specific essential genes. These platform specific 407 essential genes were enriched in diverse pathways and demonstrated unique genomic 408
attributes. Interestingly we also found that shRNA screens are often more predictive of 409 drug efficacy results than CRISPR screens, again stressing the important biological 410 differences between platforms.
412
Based on these findings, we concluded that the combination of both screens led to better 413 identification of "gold-standard" essential genes. We developed ECLIPSE, a machine 414 learning model to predict cell line-specific PSE, that demonstrated high accuracy, 415 sensitivity, and specificity, without the input of prior LoF screens. As seen within our 416 results, the AUPRC was substantially lower than the AUC across all classifiers. This is 417 due to the severe imbalance between essential and non-essential genes. Although AUC 418
is routinely used as a performance metric in classification models, it can be misleading in 419
cases of high-class imbalance, such as this one, due to AUC weighing classification 420 errors in both classes equally. Since essentiality is a rarity amongst protein-coding genes, 421
our While ECLIPSE shows significant predictive power in identifying genes that will be called 435
as essential by both platforms and platform specific essential genes, we are limited by 436 inherent noise within shRNA screenings. While in recent work there has been an 437 overwhelming number of CRISPR design tools available, the analytics of shRNA 438 screenings are being overlooked. We found using the LoF screening results that shRNA 439 outperformed CRISPR in drug prioritization and believe this was not captured in the 440
predicted results due to the uncharacterized noise within shRNA experiments. As 441 additional work is done to evaluate the efficacy and accuracy of shRNA screens, we 442 believe this data can easily be incorporated into our model to improve upon this work. 443
Additionally, as more optimized libraries for CRISPR 39 are performed in large scale 444 screenings we believe our reliance on CRISPR analytic tools will decrease. 445 446
Our approach has the potential to inform experimentation, while simultaneously 447 enhancing the understanding of gene essentiality. ECLIPSE can be used, prior to 448 performing shRNA or CRISPR on a set of genes, for better hit prioritization. In addition, 449
the success of ECLIPSE in diverse cell lines allows it to be used to find candidate 450 essential genes on any cell line of interest. Prioritization of drug treatment in specific 451 primary sites can also be informed by the cell-line specific essentiality profile. Overall our 452 results characterize the effects of mechanistic differences between shRNA and CRISPR, 453
while providing a predictive model, ECLIPSE, which can be used to better understand 454 gene essentiality, which can lead to real clinical impact. 455 456 METHODS 457 458
Genome-wide Loss-of-Function Data 459
The loss-of-function essentiality data was downloaded via DepMap. The shRNA and 460 CRISPR LoF screening results were collected from DepMap 18Q4 13, 40 . Pre-calculated 461 DEMETER and CERES values were used to determine essentiality. Scores were then 462 paired together for each gene in each specific cell line cell line creating ~4.5 million cell 463 line-gene pairs. Essential genes for each cell line were determined with a top 5% 464 essentiality score cut off. For each gene the percent of the total cell lines of the 379 that 465 a gene was marked essential within for each platform was found. 466 467
Feature Collection 468 469
Genomic Features 470
For the 14830 genes tested on each platform multiple gene features were collected. Cell 471 line specific mRNA expression and DNA copy number data was downloaded from the 472
Cancer Cell Line Encyclopedia (CCLE). GISTIC 2.0 was used to calculate copy numbers 473 through GenePattern. Conservation scores were found by using web-based tool 474 CANDID 41 . The ExAC database provided mutational prevalence data, missense z score 475 and the probability of loss-of-function intolerance 21 . The transcription-factor regulation 476 status of a gene was found by downloading from ENCODE. Genes being regulate by 2/3 477 or more TFs were classified as being highly regulated. 478 479
Network Features 480
We curated a biological network that contains 22,399 protein-coding genes, 6,679 drugs, 481
and 170 TFs. The protein-protein interactions represent established interaction 42-44 , which 482
include both physical (protein-protein) and non-physical (phosphorylation, metabolic, 483 signaling, and regulatory) interactions. The drug-protein interactions were curated from 484 several drug target databases 44 . 485 486
sgRNA Features 487
The sgRNAs used within the genome-wide CRISPR screens that contributed to each 488 gene's essentiality score was found and downloaded via Project Achilles. E-CRISPR, a 489 web based tool, was run to determine Xu-score, exon score, and GC content 26, 45, 46 ..
490
Additionally, the FORECasT algorithm was used to predict if sgRNAs will cause an 47 out 491 of frame mutation. 492 493 494 KEGG Pathway Analysis 495 KEGG pathway over representation was found using Limma R package 48 for all genes 496 marked as essential by shRNA and CRISPR. For each cell line the pathways that were 497 significantly over represented were found and ranked for each platform. Then the rank 498 statistic (the sum of the ranks of the length of cell lines) was found for each platform. 499 500
Cross Platform Correlation 501
Across all cell lines the correlation between CRISPR LoF scores and shRNA LoF scores 502
were found for each gene. The genes with the top 100 and bottom 100 Pearson 503 coefficients were classified as being positively correlated and negatively correlated, 504
respectively. The genes with the middle 100 Pearson coefficients were classified as 505 having no correlation. For RPKM expression, CANDID conservation scores, gene degree 506 and gene betweenness a Kolmogorov-Smirnov test was performed between the negative 507
and positive correlated genes. The enrichment of highly regulated genes was found using 508 a Fisher's exact test. 509 510
The ECLIPSE Model 511 ECLIPSE was trained using the features described above on the DepMap data of 379 512 overlapping cell lines. Random forest, a decision tree model, was used after model 513 selection and implemented using the R statistical software with the randomForest 514 package 49 . To evaluate predictive power 10-fold cross validation was used. For the binary 515 models predicting essentiality class, down sampling was the chosen sub-sampling 516 approach applied to each fold to account for class imbalances. 517 518
Classification Evaluation 519
For evaluating all the binary essentiality classifications, receiver operating characteristic 520
(ROC) and precision-recall curve (PRC) curves were created in R using the pROC 50 and 521 precrec 51 packages respectively. Area-under-the-ROC curve (AUC) and area-under-the-522 PRC (AUPRC) scores were used to evaluate model performance.
524
Drug Pharmacological Inhibition Analysis 525
Drug efficacy values for 60 drugs and 374 cell lines were downloaded from The Genomics 526
of Drug Sensitivity in Cancer Project 52 . All drug targets were obtained from DrugBank 527
Version 5.0 with a custom python web scrapping script 53 . 528 529
Known Drug Efficacy 530
Drugs were narrowed down to those with targets that had both shRNA and CRISPR 531 essentiality values available. 170 cell lines were found to have drug sensitivity data 532 available for these drugs. A Kolmogorov-Smirnov test was performed between drugs with 533 at least one target found to be essential, according to different essentiality classifications, 534
and those that were not. 535 536
Predicted Drug Target Essentiality 537
In total, we tested 60 drugs with known targets and drug sensitivity data available in 374 538 cell lines, cell lines used to train the model were excluded. For each target ECLIPSE was 539 run to obtain essentiality predictions within each of the 213 cell lines. For each group a 540
Kolmogorov-Smirnov test was performed to determine the cell line sensitivity difference 541
between drugs with a least one target predicted to be essential in that cell line and those 542 with none, for each essentiality class. 543 544
Approved Anti-Cancer Drug Analysis 545
All approved drug indications were obtained from DrugBank Version 5.0 with a custom 546 python web scrapping script 53 . In addition, clinical trial information was collected from 547
AACT, a relational database with all clinicaltrial.gov information, using a custom R script. 548 549
We evaluated 6,013 drugs with available indication and target data, 333 being approved 550 or within clinical trials for neoplastic diseases that we could accurately match to a cancer 551 type included in our training set. For each drug the representative ECLIPSE score was 552 the maximum ECLIPSE score of all targets of the maximum score of those targets in all 553 cell lines of the matching primary site. A target score was also calculated which was a 554 modification of the ECLIPSE score. First each gene was given a cell line normalized 555 score, which was all the predicted scores for that gene across all cell lines normalized 556
from 0-1. The average of that normalized score and the predicted score was then used 557
as the Target Score. The maximum Target Score across all drug targets in all cell lines 558 of a given primary site was used for each drug, similar to ECLIPSE score. A Mann-559
Whitney test was used to find the difference in predicted scores between drugs approved 560
for cancer treatment versus drugs that are not approved or investigated for cancer 561 treatment. 562 563
Novel Drug Indication Analysis 564
To predict possible repurposing opportunities, we used the list of 6,013 non-cancer drugs. 565
This was refined to include only approved drugs and those that did not share any 566 molecular targets with approved cancer drugs. We then ranked drugs based on their 567 target score, CRISPR LoF screening results 40 , shRNA LoF screening results 13 or gene 568 expression. For LoF screenings the minimum score of all known targets across all cell 569 lines of the appropriate primary site was used. For expression data the maximum RPKM, 570
collected from CCLE 54 , of all targets across all cell lines of the matching primary site was 571
used. The comparison of ranks was then used to identify novel cancer therapeutics. 572 573
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